文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌患者合并症与竞争风险评分的系统综述

Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.
PubMed 文献 · Eur Urol Oncol · 2018-06-06

该系统综述检索1970至2017年文献,评估膀胱癌术前合并症风险评估(CRA)工具。无随机对照试验比较CRA工具;接受根治性膀胱切除术且合并症与体能评分均高风险者,其他原因死亡风险可高达低评分者的7倍。Charlson合并症指数研究最广,90天围手术期死亡率及总生存和癌特异生存的ROC曲线下面积可达0.810。

要点

  • 合并症与体能评分均高者,根治性膀胱切除术后其他原因死亡风险可高达低评分者的7倍。
  • Charlson合并症指数对90天围手术期死亡率及生存的ROC曲线下面积可达0.810。
  • 竞争风险评估工具缺乏,需进一步比较研究指导治疗决策。

核心结论

  • CRA工具应纳入术前治疗咨询和术后结局评估。
  • 回顾性证据支持膀胱癌使用CRA工具,但需进一步比较研究评估其有效性并识别最可能从竞争风险评估指导的治疗中获益的患者。

研究设计与样本

  • 系统综述,遵循PRISMA指南,检索Ovid和Medline,纳入1970至2017年报告膀胱癌合并症风险评估工具的前瞻性和回顾性研究。

主要发现

  • 无已发表的随机对照试验比较膀胱癌CRA工具。
  • 接受根治性膀胱切除术且合并症与体能评分均高风险者,其他原因死亡风险可高达低评分者的7倍。
  • Charlson合并症指数是研究最广的指数之一,用于90天围手术期死亡率及总生存和癌特异生存,ROC曲线下面积可达0.810。
  • 膀胱癌CRA工具的前瞻性研究一致显示合并症越高结局越差。
  • 竞争风险评估工具缺乏,评估这些工具对患者和提供者治疗决策影响的研究有限。

关键数值与推荐

  • Charlson合并症指数:90天围手术期死亡率及总生存和癌特异生存的ROC曲线下面积可达0.810。
  • 合并症与体能评分均高风险者,其他原因死亡风险可高达低评分者的7倍。

临床怎么用

  • 将CRA工具纳入术前治疗咨询和术后结局评估。
  • 讨论治疗选择时,将合并症风险纳入实践指南。

局限性

  • 无随机对照试验比较CRA工具。
  • 竞争风险评估工具缺乏,评估其对治疗决策影响的研究有限。
  • 需进一步比较研究评估CRA工具有效性并识别最可能获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Radical cystectomy continues to be associated with a significant risk of morbidity and all-cause mortality (ACM). Practice pattern data demonstrating underuse of surgery for patients with muscle-invasive and high-risk non-muscle invasive bladder cancer (BC) have been linked to the advanced age and higher comorbidity status of such patients, which suggests that rates of ACM as well as cancer-specific mortality should be incorporated into patient counseling and guideline recommendations. OBJECTIVE: To review the literature on risk assessment tools for preoperative comorbidity in BC that may aid in treatment decision-making. EVIDENCE ACQUISITION: A systematic search was conducted using Ovid and Medline according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies between 1970 and 2017 reporting on comorbidity risk assessment (CRA) tools for BC. Prospective and retrospective studies were included. EVIDENCE SYNTHESIS: There are no published randomized control trials comparing CRA tools for BC. Patients undergoing radical cystectomy with combined high-risk comorbidity and performance scores may face up to a sevenfold greater risk of other-cause mortality compared to those with low scores. The Charlson Comorbidity Index is one of the most widely studied indices for 90-d perioperative mortality and overall and cancer-specific survival, with an area under the receiver operating characteristic curve of up to 0.810. Prospective studies of CRA tools for BC have consistently shown that patients with higher comorbidity have worse outcomes. While not specific for BC, comorbidity indices provide useful assessment of competing risks. Competing-risks assessment tools are lacking, with limited studies assessing the impact of these tools on treatment decision-making by patients and providers. We provide the impetus for incorporation of comorbidity risks into practice guidelines when discussing treatment options with patients. CONCLUSIONS: CRA tools should be incorporated into preoperative treatment counseling and the assessment of postoperative outcomes. While retrospective evidence supports the use of CRA tools for BC, further comparative studies evaluating the effectiveness of these tools and identifying the patients most likely to benefit from a treatment according to competing-risks assessment are needed. PATIENT SUMMARY: In this review we explored the clinical evidence for comorbidity risk assessment tools in bladder cancer. We found evidence to support incorporation of comorbidity risks into practice guidelines when discussing treatment options with patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Williams SB, Kamat AM, Chamie K, et al. Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. Eur Urol Oncol. 2018. PMID: 30345422. doi:10.1016/j.euo.2018.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。